{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:26:42Z","timestamp":1793039202282,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cmi.2016.05.030","type":"journal-article","created":{"date-parts":[[2016,6,12]],"date-time":"2016-06-12T11:00:46Z","timestamp":1465729246000},"page":"815.e1-815.e3","source":"Crossref","is-referenced-by-count":43,"title":["Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications"],"prefix":"10.1016","volume":"22","author":[{"given":"T.-L.","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.05.030_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12660","article-title":"Invasive fungal infections in solid organ transplant recipients","volume":"20","author":"Gavald\u00e0","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.05.030_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1469-0691.2011.03741.x","article-title":"Immunotherapy of Cryptococcus infections","volume":"18","author":"Antachopoulos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.05.030_bib3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1086\/587101","article-title":"When primary antifungal therapy fails","volume":"46","author":"Nucci","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.05.030_bib4","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1136\/annrheumdis-2013-203407","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2016.05.030_bib5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Kourbeti","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.05.030_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cmi.2016.05.030_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/322597","article-title":"Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy","volume":"33","author":"Pappas","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.05.030_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3201\/eid0703.017302","article-title":"Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome","volume":"7","author":"Husain","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2016.05.030_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/1545109712459077","article-title":"Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation","volume":"11","author":"Jarvis","year":"2012","journal-title":"J\u00a0Int Assoc Physicians AIDS Care (Chic)"},{"key":"10.1016\/j.cmi.2016.05.030_bib10","first-page":"1368","article-title":"Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia","volume":"60","author":"Phillips","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.05.030_bib11","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","article-title":"Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case\u2013control analysis","volume":"71","author":"Dixon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2016.05.030_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cmi.2016.05.030_bib13","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.4049\/jimmunol.157.10.4529","article-title":"Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans","volume":"157","author":"Huffnagle","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2016.05.030_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2005.01.004","article-title":"Clinical pharmacokinetics of TNF antagonists: how do they differ?","volume":"34","author":"Nestorov","year":"2005","journal-title":"Semin Arthritis Rheum"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16301823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16301823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T21:30:27Z","timestamp":1692394227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16301823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1198743X16301823"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.05.030","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}